Andreas Argyrides
Stock Analyst at Oppenheimer
(4.28)
# 349
Out of 5,180 analysts
124
Total ratings
50.93%
Success rate
16.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Initiates: Outperform | $10 | $4.35 | +129.89% | 1 | Mar 16, 2026 | |
| LQDA Liquidia | Maintains: Underperform | $16 → $19 | $35.18 | -45.99% | 8 | Mar 12, 2026 | |
| GOSS Gossamer Bio | Maintains: Outperform | $12 → $3 | $0.32 | +837.50% | 9 | Mar 5, 2026 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $588.36 | +1.98% | 2 | Feb 26, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $30 → $35 | $16.93 | +106.73% | 15 | Feb 24, 2026 | |
| EVMN Evommune | Initiates: Outperform | $42 | $22.00 | +90.91% | 1 | Jan 22, 2026 | |
| DYN Dyne Therapeutics | Upgrades: Outperform | $11 → $40 | $17.09 | +134.06% | 5 | Dec 10, 2025 | |
| SVRA Savara | Maintains: Outperform | $8 → $9 | $5.05 | +78.22% | 2 | Nov 14, 2025 | |
| KROS Keros Therapeutics | Reiterates: Outperform | $23 → $27 | $10.68 | +152.81% | 9 | Nov 12, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Outperform | $77 → $115 | $53.29 | +115.80% | 2 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $21 | $4.31 | +387.24% | 2 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $29 | $10.06 | +188.27% | 2 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $33 | $0.17 | +19,198.25% | 2 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $2.37 | +532.91% | 2 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $20 | $4.23 | +372.81% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $61 | $26.90 | +126.77% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 → $7 | $4.04 | +73.27% | 5 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $3 | $0.83 | +260.71% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $4 | $0.76 | +424.18% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $155 → $90 | $10.28 | +775.49% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $9 | $1.51 | +496.03% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $218.35 | -17.11% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $7.82 | +143.12% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $24.55 | +18.13% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $7.77 | +170.27% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $20.48 | +993.75% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $23.27 | +144.95% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $1.03 | +579.61% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.31 | +3,154.15% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $54.79 | +27.76% | 6 | Aug 1, 2023 |
Opus Genetics
Mar 16, 2026
Initiates: Outperform
Price Target: $10
Current: $4.35
Upside: +129.89%
Liquidia
Mar 12, 2026
Maintains: Underperform
Price Target: $16 → $19
Current: $35.18
Upside: -45.99%
Gossamer Bio
Mar 5, 2026
Maintains: Outperform
Price Target: $12 → $3
Current: $0.32
Upside: +837.50%
United Therapeutics
Feb 26, 2026
Maintains: Outperform
Price Target: $575 → $600
Current: $588.36
Upside: +1.98%
MoonLake Immunotherapeutics
Feb 24, 2026
Maintains: Outperform
Price Target: $30 → $35
Current: $16.93
Upside: +106.73%
Evommune
Jan 22, 2026
Initiates: Outperform
Price Target: $42
Current: $22.00
Upside: +90.91%
Dyne Therapeutics
Dec 10, 2025
Upgrades: Outperform
Price Target: $11 → $40
Current: $17.09
Upside: +134.06%
Savara
Nov 14, 2025
Maintains: Outperform
Price Target: $8 → $9
Current: $5.05
Upside: +78.22%
Keros Therapeutics
Nov 12, 2025
Reiterates: Outperform
Price Target: $23 → $27
Current: $10.68
Upside: +152.81%
Monopar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $77 → $115
Current: $53.29
Upside: +115.80%
Oct 2, 2025
Maintains: Outperform
Price Target: $26 → $21
Current: $4.31
Upside: +387.24%
Sep 16, 2025
Maintains: Outperform
Price Target: $35 → $29
Current: $10.06
Upside: +188.27%
Sep 11, 2025
Maintains: Outperform
Price Target: $15 → $33
Current: $0.17
Upside: +19,198.25%
Sep 5, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $2.37
Upside: +532.91%
Aug 15, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $4.23
Upside: +372.81%
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $26.90
Upside: +126.77%
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $4.04
Upside: +73.27%
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $0.83
Upside: +260.71%
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $0.76
Upside: +424.18%
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $10.28
Upside: +775.49%
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $1.51
Upside: +496.03%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $218.35
Upside: -17.11%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $7.82
Upside: +143.12%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $24.55
Upside: +18.13%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $7.77
Upside: +170.27%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $20.48
Upside: +993.75%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $23.27
Upside: +144.95%
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $1.03
Upside: +579.61%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.31
Upside: +3,154.15%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $54.79
Upside: +27.76%